DNA X Inc (SONM)

DNA X Inc is a common stock listing on NASDAQ for a company that develops enterprise 5G communications equipment and related software. Through its operating business, the company provides rugged mobile phones for field and task workers, including the Sonim XP10, XP5plus, XP3plus, XP Pro, XP100 4G, XP400 5G, and XP3plus 5G rugged flip phones. Its connected solutions also include fixed wireless access and mobile hotspot devices such as the Sonim H100, H700, and H500-series products, along with SonimWare software and industrial-grade accessories. DNA X sells through wireless carriers, distributors, communications system integrators, and electronics resellers, serving industries such as transportation and logistics, construction, manufacturing, facilities management, energy and utilities, mining, federal government, and public safety. The company was previously known as Sonim Technologies, Inc., adopted the DNA X name in January 2026, and is headquartered in San Diego, California.


Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-SONM
$3.10
8.9% Upside
Fair
Weak
0.0%
August 7, 2026
-0.4x
-4.3x
4.346 M
2.821 M
19.8%
81.3%
-91.5
159.2%
Valuation • Fair Value

DNA X Inc (NASDAQ-SONM) Fair Value by Valuation Model

Compare the primary fair value estimate for DNA X Inc (NASDAQ-SONM) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$3.10

Estimated upside of 8.9% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$3.10

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for DNA X Inc (NASDAQ-SONM) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for DNA X Inc (NASDAQ-SONM)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

143.2 M

Forward revenue estimate.

EBITDA

-3.834 M

Current operating profitability reference.

EBITDA Forecast

9.22 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review DNA X Inc (NASDAQ-SONM) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for DNA X Inc (NASDAQ-SONM)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

-91.5

Lower score that deserves closer risk review.

FCF / Net Income

159.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for DNA X Inc (NASDAQ-SONM). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for DNA X Inc (NASDAQ-SONM)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 7, 2026

Days to Earnings

17

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for DNA X Inc (NASDAQ-SONM), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

DNA X Inc (NASDAQ-SONM) Stock Forecast & Technical Outlook

Review DNA X Inc (NASDAQ-SONM) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for DNA X Inc (NASDAQ-SONM) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for DNA X Inc (NASDAQ-SONM) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for DNA X Inc (NASDAQ-SONM) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for DNA X Inc (NASDAQ-SONM) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for DNA X Inc (NASDAQ-SONM) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for DNA X Inc (NASDAQ-SONM)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for DNA X Inc (NASDAQ-SONM) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ Fast Investor Answers

DNA X Inc (NASDAQ-SONM) Stock FAQ

Quick answers about DNA X Inc (NASDAQ-SONM) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$3.10
Estimated upside 8.9%
Valuation Rating
Undervalued
Estimated upside of 8.9%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for DNA X Inc (NASDAQ-SONM) is $3.10. This implies an estimated upside of 8.9% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 8.9% versus the current market price.

An analyst price target for DNA X Inc (NASDAQ-SONM) is not currently available in the latest data file.

The current financial health read for DNA X Inc (NASDAQ-SONM) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for DNA X Inc (NASDAQ-SONM) is August 7, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for DNA X Inc (NASDAQ-SONM) is -0.4x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for DNA X Inc is 4.346 M.

The current enterprise value listed for DNA X Inc is 2.821 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for DNA X Inc is NASDAQ-SONM, and the stock is listed on NASDAQ.

DNA X Inc (NASDAQ-SONM) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for DNA X Inc is 19.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for DNA X Inc is 81.3%. Free float helps investors understand how much of the share base is available for public trading.